Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics Closes $13M Financing Investment

NEW YORK – Interpace Diagnostics said today that it has closed on a $13 million convertible preferred stock investment by Ampersand Capital Partners. 

The Parsippany, New Jersey-based company noted that the investment is the second tranche of the $27 million convertible preferred stock financing provided by Ampersand to finance Interpace's acquisition of Cancer Genetics' biopharma business in July. 

According to Interpace, about $6 million of the financing will be used to pay down a note due to Cancer Genetics in connection with the acquisition. 

"We are excited to strengthen our partnership with Ampersand and to reinforce it through overwhelming support from our shareholders as we received approval for the second tranche financing," Interpace CEO Jack Stover said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more